About: Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity
Creator	Perkmann, Thomas Binder, Christoph Hartl, Sylvia Strassl, Robert Aletaha, Daniel Breyer, Marie-Kathrin Breyer-Kohansal, Robab Burghuber, Otto Haslacher, Helmuth Marculescu, Rodrig Mucher, Patrick Perkmann-Nagele, Nicole Quehenberger, Peter Sieghart, Daniela Wagner, Oswald
Source	MedRxiv
abstract	Background: In the context of the COVID-19 pandemic, numerous new serological test systems for the detection of anti-SARS-CoV-2 antibodies have become available quickly. However, the clinical performance of many of them is still insufficiently described. Therefore we compared three commercial, CE-marked, SARS-CoV-2 antibody assays side by side. Methods: We included a total of 1,154 specimens from pre-COVID-19 times and 65 samples from COVID-19 patients ([≥]14 days after symptom onset) to evaluate the test performance of SARS-CoV-2 serological assays by Abbott, Roche, and DiaSorin. Results: All three assays presented with high specificities: 99.2% (98.6-99.7) for Abbott, 99.7% (99.2-100.0) for Roche, and 98.3% (97.3-98.9) for DiaSorin. In contrast to the manufacturers' specifications, sensitivities only ranged from 83.1% to 89.2%. Although the three methods were in good agreement (Cohen's Kappa 0.71-0.87), McNemar's test revealed significant differences between results obtained from Roche and DiaSorin. However, at low seroprevalences, the minor differences in specificity resulted in profound discrepancies of positive predictability at 1% seroprevalence: 52.3% (36.2-67.9), 77.6% (52.8-91.5), and 32.6% (23.6-43.1) for Roche, Abbott, and DiaSorin, respectively. Conclusion: We find diagnostically relevant differences in specificities for the anti-SARS-CoV-2 antibody assays by Abbott, Roche, and DiaSorin that have a significant impact on the positive predictability of these tests.
has issue date	2020-06-05(xsd:dateTime)
bibo:doi	10.1101/2020.06.04.20117911
has license	medrxiv
sha1sum (hex)	a73a02a9097483e778f6ac110c1477b81aa64dc7
schema:url	https://doi.org/10.1101/2020.06.04.20117911
resource representing a document's title	Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity
resource representing a document's body	covid:a73a02a9097483e778f6ac110c1477b81aa64dc7#body_text
is schema:about of	named entity 'tested positive' named entity 'SARS-CoV-2' named entity 'HKU1' named entity 'coronaviruses' named entity 'medRxiv' named entity 'SARS-CoV-2' named entity 'peer review' named entity 'peer review' named entity 'peer review' named entity 'antibodies' named entity 'MedCalc' named entity 'SARS-CoV-2' named entity 'cross-reactivity' named entity 'nucleocapsid' named entity 'sensitivity and specificity' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'preprint' named entity 'antibodies' named entity 'DiaSorin' named entity 'preprint' named entity 'DiaSorin' named entity 'DiaSorin' named entity 'IgG' named entity 'peer review' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'medical care' named entity 'medRxiv' named entity 'preprint' named entity 'false-negative' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'preprint' named entity 'Roche' named entity 'epidemiological' named entity 'Ostend' named entity 'false-positives' named entity 'IgG' named entity 'protein' named entity 'serum' named entity 'SARS-CoV-2' named entity 'Roche' named entity 'NPV' named entity 'antibody' named entity 'antibodies' named entity 'OC43' named entity 'RT-PCR' named entity 'peer review' named entity 'SARS-CoV-2' named entity 'Roche' named entity 'antibodies' named entity 'medRxiv' named entity 'specificity and sensitivity' named entity 'virulent' named entity 'peer review' named entity 'RT-PCR' named entity 'serological' named entity 'COVID' named entity 'plasma' named entity 'RT-PCR' named entity 'explanatory power' named entity 'NL63' named entity 'Roche' named entity 'serum' named entity 'medRxiv' named entity 'IgG' named entity 'DiaSorin' named entity 'sensitive and specific' named entity 'preprint' named entity 'antibody'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software